Merck increased revenue by 19% in nine months

In the first nine months of 2016, the global net sales of pharmaceutical company Merck amounted to €11.2 billion, which is 19.3% more than in the same period of 2015. The company expects that by the end of 2016, sales will reach €15 billion, and EBITDA before special items will be about €4.5 billion.

In the first nine months of 2016, EBITDA before special items grew by 26.7% compared to the previous year and amounted to €3.4 billion, which the company attributes to strong sales growth in the Life Science and Healthcare sectors.

The Healthcare sector saw moderate organic growth, achieving net sales of €5.1 billion. Global sales in the Life Science sector for the first nine months of 2016 increased by 85.8% compared to the same period in 2015 and amounted to €4.2 billion.

The company attributes these high figures to the completed acquisition of the world-renowned laboratory reagent producer Sigma-Aldrich in 2015.

In 2016, Merck internationally announced the launch of a new model of research centers, M-Lab, designed for collaboration with partners and clients. The new centers provide the opportunity to simulate a biopharmaceutical or biotechnological production process for conducting experiments, troubleshooting, and promptly solving emerging problems. The first M-Lab center in Russia is expected to open in 2017.

Merck is a German pharmaceutical company founded in 1668. Its main areas are pharmaceutical, chemical, and bio-medical products. About 30% of the company's shares are traded on the stock exchange, and the Merck family, which owns 70% of the company, manages it through the general partner – E. Merck KG. In 2015, the company's sales amounted to €12.8 billion across 66 countries.